Delgocitinib is a JAK inhibitor that blocks the activation of the JAK-STAT pathway which has been shown to play a key role in the pathophysiology of chronic inflammatory skin diseases.

and 50.4 percent of those with one and two or more moderate risk factors were recommended aspirin prophylaxis.

Tabelecleucel, an allogeneic, EBV-specific T-cell immunotherapy, works by targeting and eliminating EBV-infected cells.

HealthDay News — More than 100,000 Rich’s Ice Cream Co. bars have been recalled due to possible listeria contamination. The affected ice cream bars were sold across 23 states and in Nassau, capital of ...

Gefurulimab is a dual-binding nanobody designed to bind to the C5 protein in the terminal complement cascade and prevent the overactivation of the body’s immune system.

HealthDay News — The US Food and Drug Administration has appointed George Francis Tidmarsh, MD, PhD, as director of the Center for Drug Evaluation and Research (CDER).

HealthDay News — Omalizumab and remibrutinib may be the most effective treatments for reducing hives, itch, and swelling with chronic urticaria, according to a study published online July 15 in the ...

The first recall affects tuna salad and ready-to-eat foods containing tuna salad from Beaverton, Oregon-based Reser's Fine Foods.

The ABTECT clinical program included the randomized, double-blind, placebo-controlled phase 3 ABTECT-1 and ABTECT-2 trials.

Older age, Black race, very low Child Opportunity Index, public insurance linked to lower rates of nirsevimab receipt ...

Researchers recommended that regulators consider mandating head-to-head trials comparing next-in-class and against existing in-class agents when possible.

Tildrakizumab is an interleukin-23 antagonist approved under the brand name Ilumya for the treatment of plaque psoriasis.